The third phase of the initiative focuses on proactively creating a fundamental shift in the mindset of government sector employees
The Serum Institute of India is expected to create a new Omicron-specific vaccine within six months.
According to NDTV, institute chief Adar Poonawalla says the pharma giant is already working with US biotech company Novavax to develop a vaccine against Omicron sub-variant BA-52.
"Think this vaccine is important as a booster," said Poonawalla, adding that Omicron is "not mild" and often manifests like a "serious flu."
However, the vaccine can only enter the market once approved by national regulators; it is not clear whether a separate Indian clinical trial is needed.
"Trials of Novavax are in progress in Australia currently. By November-December should be in a position to approach the US drug regulator," Mr Poonawalla said.
ALSO READ:
Omicron variants, such as B5 and B2, are currently making their rounds in the Indian capital of Delhi, where authorities say they are more infectious than the base variant.
The third phase of the initiative focuses on proactively creating a fundamental shift in the mindset of government sector employees
Thai ambassador noted that completion of the agreement and strong participation in the upcoming COP28 are his top priorities in the coming months
Let's seek a life where every day fulfils our passions, not just a countdown to the next SMS
More than 180 Arab citizens in Israel have been killed in crime-related violence since January — a seven-year high — in a spate of killings
Could a constitutional provision adopted in 1868 really save American democracy in 2024?
Chasing 353, the Indians were all out for 286
During the Arab Media Forum, the Emirati astronaut also spoke of how much his father taught him, despite not attending college himself
The superstar regularly replies to fan messages on X (formerly known as Twitter) every Tuesday